ArticleCell reports2018
An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections.
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 124 citations in OpenAlex.
- Pathogenesis and neurotropism of a contemporary Powassan virus lineage II strain in mice.Journal of virology · 2026Article
- A DNA-guided prokaryotic argonaute enables programmable RNA cleavage for sequencing and quality control ofMolecular therapy. Nucleic acids · 2026Article
- Biogenic nanomaterials: A green strategy for sustainable vector-borne disease management.Pest management science · 2026Review
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Powassan virus.Trends in microbiology · 2026Article
- mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection.Viruses · 2026Article
- Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations.International journal of molecular sciences · 2026Review
- Characterization of virus neuroinvasion, blood-brain barrier integrity and neuroinflammation following Powassan virus infection in mice.Frontiers in immunology · 2026Article
- Pathogenicity and virulence of Powassan virus.Virulence · 2025Review
- Review
- mRNA lipid nanoparticle formulation, characterization and evaluation.Nature protocols · 2025Review
- The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.NPJ vaccines · 2025Article
- Innate Immune Response to Powassan Virus Infection: Progress Toward Infection Control.Vaccines · 2025Review
- Review
- Interferon-alpha/beta receptor deficiency enhances susceptibility to Powassan virus infection in mice.Frontiers in microbiology · 2025Article
- Powassan Virus Encephalitis in an Immunocompromised Patient: A Diagnostic Challenge With Case Report and Literature Review.Case reports in infectious diseases · 2025Article
- Review
- Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects.International journal of molecular sciences · 2024Review
- Age-dependent Powassan virus lethality is linked to glial cell activation and divergent neuroinflammatory cytokine responses in a murine model.Journal of virology · 2024Article
- Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.Vaccine: X · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Powassan virus (POWV) is an emerging tick-transmitted flavivirus that circulates in North America and Russia. Up to 5% of deer ticks now test positive for POWV in certain regions of the northern United States. Although POWV infections cause life-threatening encephalitis, there is no vaccine or countermeasure available for prevention or treatment. Here, we developed a lipid nanoparticle (LNP)-encapsulated modified mRNA vaccine encoding the POWV prM and E genes and demonstrated its immunogenicity and efficacy in mice following immunization with one or two doses. The POWV mRNA vaccine induced high titers of neutralizing antibody and sterilizing immunity against lethal challenge with different POWV strains. The mRNA vaccine also induced cross-neutralizing antibodies against multiple other tick-borne flaviviruses and protected mice against the distantly related Langat virus. These data demonstrate the utility of the LNP-mRNA vaccine platform for the development of vaccines with protective activity against multiple flaviviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.